Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06QKW
|
|||
| Former ID |
DIB019143
|
|||
| Drug Name |
cirazoline
|
|||
| Synonyms |
cirazoline; Cirazoline [INN]; Cirazolinum [INN-Latin]; Cirazolina [INN-Spanish]; UNII-QK318GVY3Y; 59939-16-1; LD-3098; QK318GVY3Y; CHEMBL13852; NCGC00015196-04; 2-((o-Cyclopropylphenoxy)methyl)-2-imidazoline; DSSTox_CID_25131; DSSTox_RID_80692; DSSTox_GSID_45131; Cirazolina; Cirazolinum; 1H-Imidazole, 2-((2-cyclopropylphenoxy)methyl)-4,5-dihydro-; 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole; CAS-59939-16-1; LD 3098; Tocris-0888; Lopac-C-223; AC1L1EEZ; Lopac0_000354; KBioGR_000306; BSPBio_001586; KBioSS_000306; GTPL515
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C13H16N2O
|
|||
| Canonical SMILES |
C1CC1C2=CC=CC=C2OCC3=NCCN3
|
|||
| InChI |
1S/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15)
|
|||
| InChIKey |
YAORIDZYZDUZCM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59939-16-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4816529, 7978952, 8151786, 11110893, 11113761, 11120292, 11120780, 11121268, 11121651, 11122131, 11362720, 11365282, 11367844, 11370711, 11370712, 11373445, 11376006, 12012735, 14993968, 26751944, 26751945, 29221920, 47364966, 47440014, 48334242, 49979380, 50104620, 50104621, 50891172, 57321445, 85209513, 85788752, 90341611, 92098522, 92308777, 92310002, 99300914, 99302434, 103175726, 103936642, 104171120, 104301544, 124749647, 124879511, 124879512, 124879513, 124879514, 124879515, 129767852, 135027726
|
|||
| ChEBI ID |
CHEBI:92950
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Agonist | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 515). | |||
| REF 2 | Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.